Stocks · News reference
Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-25 AccNo: 0001193125-26-365287 Size: 203 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgarHC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.
Read original at benzingaBaird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.
Read original at benzingaUS stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected loss and lower revenue outlook.
Read original at benzinga